Clinical Trials

Multiple clinical trials sponsored by Tyme Inc. have evaluated the safety, pharmacokinetics, and efficacy of Racemetyrosine (SM-88) in early to mid-phase settings for advanced, hormone-associated solid tumors. These Phase 1/2 studies included a completed clinical trial evaluating oral SM-88 in prostate cancer patients with rising prostate-specific antigen levels and a withdrawn clinical trial assessing ascending doses in breast cancer subjects.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02562612 Withdrawn
Breast Cancer
Tyme Inc
2022-10 Phase 1|Phase 2
NCT02796898 Completed
Prostate Cancer|Rising Prostate Specific Antigen (PSA)
Tyme Inc
2016-06 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Racemetyrosine (SM-88) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Racemetyrosine (SM-88) functions as a modified amino acid derivative that disrupts aberrant metabolic pathways, thereby interfering with protein synthesis and increasing intracellular oxidative stress in dysfunctional cell populations. This selective metabolic impairment halts cellular proliferation and induces tumor cell death, providing a therapeutic rationale for targeting aggressive malignancies such as breast cancer and prostate cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.